Abstract
A total of 29 patients with muscle invasive bladder cancer, clinical stage T2N0 (12), T3aN0 (9), T3bN0 (5), T3N2 (2) or T4N2 (1), underwent 2 to 4 cycles of neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) chemotherapy followed by either radiotherapy (15), radical cystectomy (11) or no local therapy (3). The overall response rate to M-VAC chemotherapy was 69%, with 31% clinical complete responses and 38% clinical partial responses. A functioning bladder was maintained in 55% of the responding patients, although bladder wall calcifications were observed in 4 of 15 irradiated patients. Overall survival was 71% and disease-free survival was 55% at a median followup of 57 months. For the 12 stage T2N0 cancer patients overall survival was 100% at a median followup of 52 months. For the stages T3a and T3bN0 cancer patients overall survival was 63%, while all 3 node positive patients died. Neoadjuvant chemotherapy with a modified M-VAC regimen is well tolerated and may result in bladder preservation.
References
Sep 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C J Logothetis
Sep 11, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C Y FungG R Prout
Jan 1, 1991·The Journal of Urology·P K ReddyE E Fraley
Feb 1, 1991·International Journal of Radiation Oncology, Biology, Physics·D Raghavan
Mar 1, 1991·International Journal of Radiation Oncology, Biology, Physics·R FarahR R Weichselbaum
Mar 1, 1991·The Journal of Urology·D G SkinnerS Groshen
Mar 1, 1991·The Journal of Urology·F F MarshallC B Brendler
Apr 1, 1991·The Journal of Urology·M MaffezziniB Campo
Feb 1, 1991·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N Gad el MawlaI Elsebai
Apr 19, 1990·The New England Journal of Medicine·D RaghavanJ P Richie
Sep 1, 1990·International Journal of Radiation Oncology, Biology, Physics·K J RussellT W Griffin
Nov 1, 1990·The Journal of Urology·R DreicerD L Trump
Dec 1, 1989·The Journal of Urology·M K GospodarowiczW Duncan
Feb 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L EapenL Gerig
Oct 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C J LogothetisK I Wishnow
Mar 1, 1988·The Journal of Urology·C N SternbergL R Weiselberg
Mar 1, 1988·The Journal of Urology·H I ScherV Reuter
Apr 1, 1987·The Journal of Urology·G StoterR Sylvester
Jun 1, 1987·The Journal of Urology·R G RowlandJ E Piser
Dec 1, 1987·The Journal of Urology·S D BoydJ Richardson
Dec 1, 1985·The Journal of Urology·F J MeyersF M Torti
Sep 1, 1982·The Journal of Urology·N G KockB M Philipson
Citations
Jan 1, 1995·Acta Oncologica·C N Sternberg
Mar 1, 1994·The Journal of Urology·N J VogelzangD Rukstalis
Jun 8, 2000·Annals of the New York Academy of Sciences·E ArslanR Santarelli
Apr 28, 2004·Cancer·Xavier Garcia del MuroJosep R Germà
Aug 1, 1994·The Journal of Urology·Y SumiyoshiK Maebayashi
Oct 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N J Vogelzang
Oct 24, 1997·Cancer·D T DanesiF Orefici
Nov 14, 1997·Cancer·A MokarimK Nomata
Feb 1, 1994·Critical Reviews in Oncology/hematology·G J BoslH I Scher